Safety and feasibility of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a prospective single-group phase II clinical study.

J Thorac Dis · 2024 · PMC11565305 · PMID 39552849

Europe PMC DOI

hedged sentence

0.1900

closest p · 3.8× alpha

0.1900

boldest claim

The sentences

did not reach statistical significanceP=0.19not close (p > 0.1)

However, the difference in pCR rates did not reach statistical significance (50% vs. 36%, P=0.19).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.